TURQUOISE-I part 1b: Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for hepatitis C virus infection in HIV-1 coinfected patients on darunavir

Journal of Infectious Diseases

Volumn 215, Issue 4, 2017, Pages 599-605

  Wyles, David ^a   Saag, Michael ^b   Viani, Rolando M ^c   Lalezari, Jacob ^d   Adeyemi, Oluwatoyin ^e   Bhatti, Laveeza ^f   Khatri, Amit ^c   King, Jennifer R ^c   Hu, Yiran B ^c   Trinh, Roger ^c   Shulman, Nancy S ^c   Ruane, Peter ^g  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c ABBVIE INC   (United States)

^d Quest Clinical Research   (United States)

^e Ruth M Rothstein CORE Center   (United States)

^f AIDS HEALTHCARE FOUNDATION   (United States)

^g Ruane Medical and Liver Health Institute   (United States)

Author keywords

ART; co infection; darunavir; direct acting antiviral; HCV; HIV; TURQUOISE

Indexed keywords

DARUNAVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; VIRUS RNA; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIRETROVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; RITONAVIR; SULFONAMIDE; URACIL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANEMIA; ANTIRETROVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; DEHYDRATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EC50; FATIGUE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTENTION TO TREAT ANALYSIS; IRRITABILITY; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MIXED INFECTION; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED VIROLOGIC RESPONSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; ADOLESCENT; ANALOGS AND DERIVATIVES; BODY MASS; CD4 LYMPHOCYTE COUNT; COINFECTION; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECTS; HEPACIVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANILIDES; ANTI-RETROVIRAL AGENTS; BODY MASS INDEX; CARBAMATES; CD4 LYMPHOCYTE COUNT; COINFECTION; DARUNAVIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV-1; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; RIBAVIRIN; RITONAVIR; SULFONAMIDES; URACIL; YOUNG ADULT;

EID: 85016978283     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw597     Document Type: Article

References (24)

1. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85:303-15.
2. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-41.
3. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55.
4. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8:280-8.
5. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158:329-37.
6. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370-8.
7. VIEKIRA PAK (ombitasvir, paritaprevir/ritonavir, dasabuvir) prescribing information. North Chicago, IL: AbbVie Inc., 2015.
8. EXVIERA (dasabuvir) summary of product characteristics. Maidenhead, United Kingdom: AbbVie Ltd., 2015.
9. VIEKIRAX (ombitasvir, paritaprevir/ritonavir) summary of product characteristics. Maidenhead, United Kingdom: AbbVie Ltd., 2015.
10. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV- 1: a randomized trial. JAMA 2015; 313:1223-31.
11. Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of oncedaily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-nave patients in the ARTEMIS trial. HIV Med 2013; 14:49-59.
12. Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011; 25:929-39.
13. Madruga JV, Berger D, McMurchie M, et al.; TITAN Study Group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49-58.
14. Khatri A, Dutta S, Wang H, et al. Evaluation of drug-drug interactions between hepatitis c antiviral agents ombitasvir, paritaprevir/ritonavir, and dasabuvir and HIV-1 protease inhibitors. Clin Infect Dis 2016; 62:972-9.
15. Janssen Pharmaceuticals I. Prezista (darunavir) package insert. Titusville, NJ, 2015.
16. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-82.
17. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604-14.
18. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-603.
19. Grennan JT, Loutfy MR, Su D, et al.; CANOC Collaboration. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis 2012; 205:1230-8.
20. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817-29.
21. Lee PK, Kieffer TL, Siliciano RF, Nettles RE. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 2006; 57:803-5.
22. Taiwo B, Bosch RJ. More reasons to reexamine the definition of viral blip during antiretroviral therapy. J Infect Dis 2012; 205:1189-91.
23. Molto J, Valle M, Ferrer E, et al.; DRV600 Study Group. Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. J Antimicrob Chemother 2015; 70:1139-45.
24. Nelson M, Girard PM, Demasi R, et al. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. J Antimicrob Chemother 2010; 65:1505-9.